Scientists Decode Diet From Stool DNA
Developed by researchers at the Institute for Systems Biology (ISB), the new method, called MEDI (Metagenomic Estimation of Dietary Intake), detects food-derived DNA in stool samples to estimate dietary intake. MEDI leverages stool metagenomics, which refers to sequencing all the DNA present in fecal samples (including microbial, human, and food-derived DNA). This non-invasive, data-driven approach offers an objective alternative to traditional food diaries and questionnaires, which are still the gold standard in dietary assessment but can suffer from misreporting and compliance issues.
'For decades, nutrition research has depended on self-reported diaries and questionnaires – approaches that require a high degree of effort and compliance from research participants. How many strawberries did I eat two days ago? Did I have one glass of orange juice with breakfast, or two?' said Dr. Christian Diener, lead author of the study. 'MEDI provides a solution by analyzing food-derived DNA in gut metagenomic samples, offering a convenient alternative that shows good agreement with known dietary and nutritional intake patterns.'
Key Findings:
An Alternative to Questionnaire-Based Diet Tracking: Leveraging a database of more than 400 food items and over 300 billion base pairs of genomic information, MEDI accurately detected food intake patterns in infants and adults, and across two controlled feeding studies. MEDI
Connecting Dietary Intake to Nutrition: MEDI converts the relative abundance profile of specific food items into nutrient profiles, assuming a 100 gram portion. These nutrient profiles show good agreement with data from controlled feeding studies.
Identified Diet-Related Health Risks: Without food logs, MEDI pinpointed dietary features linked to metabolic syndrome in a large clinical cohort.
'Our study represents a major leap forward in how we track diet and its impacts on human health,' said ISB Associate Professor Dr. Sean Gibbons, senior author of the study. 'With food-derived DNA signatures in stool, we now have a powerful way to measure diet and microbiome composition from the same sample, which will expand our understanding of the forces shaping the human gut microbiome, personalized nutritional responses, and disease risk.'
With further development, MEDI could transform nutrition science, epidemiological studies, and clinical trials, allowing researchers, doctors, and individuals to track diet-related health risks with unprecedented ease.
The full study is published in Nature Metabolism and can be accessed here. For media inquiries or interview requests, please contact ISB's media team at [email protected].
About ISB
Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including aging, brain health, cancer, chronic illness, infectious disease, and more. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit healthcare systems in the United States. Follow us online at isbscience.org, and on YouTube, Facebook, LinkedIn, X, Bluesky, and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
Yahoo
8 hours ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the epigenetic modulation of key cellular pathways. 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including multiple trial results, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 in combination with carboplatin and paclitaxel is designed to overcome platinum resistance by leveraging LB-100's synergistic enhancement of DNA damage and impaired repair in tumor cells. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor. LIXTE's Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Ongoing dose escalation, with expansion cohort enrollment underway Upcoming Milestone: Progression-free survival (PFS) and objective response rate (ORR) update late Q3 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with immune checkpoint blockade and chemotherapy, seeking to overcome immune resistance in this cold tumor type. Status: Actively recruiting Upcoming Milestone: Initial biomarker and response data anticipated in Q4 2025 Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma, pancreatic, and lung cancers Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. CONTACT:24/7 Market NewsEditor@ Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Yahoo
8 hours ago
- Yahoo
Healthcare Innovation Summit Africa Returns to Johannesburg
JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Healthcare Innovation Summit Africa (HISA) 2025, Africa's leading platform for exploring the latest trends and technologies shaping the healthcare industry, will return to Johannesburg on 22 – 23 October 2025 for its 10th annual edition. Organised by , the event will gather senior healthcare professionals, government leaders, innovators, and technology providers from across Africa and beyond. Themed 'Connected Care, Smarter Systems: Building a Digitally Resilient African Health Ecosystem,' HISA 2025 will feature a robust agenda that covers critical areas such as artificial intelligence (AI), the Internet of Things (IoT), robotics, telemedicine, big data analytics, and digital transformation strategies for both public and private healthcare sectors. Confirmed keynote and panel speakers include: Dr Richard Friedland, Group CEO, Netcare Dr. Boris Konrad, Neuroscientist, AI and Memory Expert, Radboudumc (Germany) Andrew Raynes, CIO & SIRO, Royal Papworth Hospital (UK) Nhlanhla Xaba, ICT Manager: Governance & Information Management, Mediclinic Rajeev Eashwari, President, South African Health Informatics Association Taryn Lotz, Head of IT, Aspen Pharmacare Craig Killeen, CEO, Medinformer Joost Pielage, CTO, Quro Medical Quantin van Rensburg, CIO, Platinum Health Medical Scheme Ish Hendricks, CEO, Netclinic With Africa's healthcare industry undergoing rapid transformation, HISA 2025 offers a unique opportunity for stakeholders to gain actionable insights and forge meaningful partnerships. Delegates will benefit from: Visionary keynote presentations from local and international thought leaders Expert-led panel discussions tackling pressing healthcare challenges and opportunities Exhibition showcases of innovative solutions, products, and services Networking opportunities with policymakers, industry leaders, and innovators Click here to register now 'HISA 2025 is not just a conference, it is where the future of African healthcare takes shape,' said the event organisers. 'The event provides a powerful platform for collaboration, innovation, and the exchange of ideas that can positively impact healthcare systems across the continent.' Event Details:Date: 22 – 23 October 2025Venue: Gallagher Convention Centre, Johannesburg, South AfricaEvent Website: About HISAThe Healthcare Innovation Summit Africa is an annual gathering of healthcare professionals, innovators, and policymakers dedicated to exploring and implementing technology-driven solutions that improve healthcare delivery across Africa. CONTACT: Media Contact: Nonhlanhla Kunene Media Contact – IT News Africa Email: events@ Tel: +27 (0)12 012 5801Sign in to access your portfolio
